Notice for mecasermin (Ipsen Pty Ltd)
Active ingredients
mecasermin
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection, solution
Indication
Mecasermin is indicated for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (severe primary IGFD).
Therapeutic area
Endocrinology